Who is the new Director at Parabilis Medicines?

Parabilis Medicines named Craig Tendler Director, announced August 25, 2026.

Which similar companies made leadership changes around the same time?

Retension Pharmaceuticals (September 10, 2026), Aquestive Therapeutics, Inc. (September 29, 2026), Os Therapies (October 1, 2026) and Azora Therapeutics, Inc. (DE) (August 29, 2026) also announced leadership changes within 45 days of Parabilis Medicines.

Parabilis Medicines Appoints Craig Tendler as Director

PUBLIC · PBLSAug 25, 2026

Position

Director

Company

Parabilis Medicines

Craig Tendler

CambridgeBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma

Description

On August 22, 2026, Parabilis Medicines appointed Craig Tendler as a director to fill a newly created vacancy on its Board of Directors. He will serve as a Class II director until the 2028 annual meeting of stockholders. Mr

Quick answer

Parabilis Medicines Appoints Craig Tendler as Director (August 25, 2026). Parabilis Medicines is based in Cambridge, Massachusetts, United States.

Who is the new Director at Parabilis Medicines?: Parabilis Medicines named Craig Tendler Director, announced August 25, 2026.
What did Parabilis Medicines announce on August 25, 2026?: On August 22, 2026, Parabilis Medicines appointed Craig Tendler as a director to fill a newly created vacancy on its Board of Directors. He will serve as a Class II director until the 2028 annual meeting of stockholders.
What does Parabilis Medicines do?: Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer.
Where is Parabilis Medicines based?: Parabilis Medicines is based in Cambridge, Massachusetts, United States.
Which similar companies made leadership changes around the same time?: Retension Pharmaceuticals (September 10, 2026), Aquestive Therapeutics, Inc. (September 29, 2026), Os Therapies (October 1, 2026) and Azora Therapeutics, Inc. (DE) (August 29, 2026) also announced leadership changes within 45 days of Parabilis Medicines.

Source: Fundz verified event record.

Other recent leadership changes in Healthcare and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Retension Pharmaceuticals Appoints LeAnne Bloedon as EVP of Clinical Development (September 10, 2026)
Richard J. Daly Appointed as Director of Aquestive Therapeutics (September 29, 2026)
OS Therapies Appoints Mr. Clem as Chief Commercial Officer and Mr. Knuettel as Chief Financial Officer (October 1, 2026)
Adial Pharmaceuticals Appoints Matthew Davidson as President and CEO (August 29, 2026)
Nurix Therapeutics Appoints Wes Burwell as Chief Human Resources Officer (August 21, 2026)
Arletta Pharma Solutions Appoints Jeannette Jager-van Dijk as Chief Executive Officer (September 1, 2026)

Who to call at Parabilis Medicines, and when

A new leader at Parabilis Medicines brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day Parabilis Medicines raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Parabilis Medicines, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Parabilis Medicines. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Parabilis Medicines

Location

30 Acorn Park Drive

Cambridge, Massachusetts, United States

About

Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of our platform to address undruggable intracellular protein-protein targets. We are additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. We are headquartered in Cambridge, Mass., and are well-capitalized, with more than $500 million raised to date from leading life sciences investors.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Parabilis Medicines changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans